“Forest Laboratories set aside $170 million related to a Justice Department investigation into its marketing and promotion of two antidepressants in the fiscal fourth quarter, when net income slid 46 percent to $92.8 million compared with last year’s fourth quarter.”

The case is being led by the U.S. Attorney’s Office for the District of Massachusetts. The case against Forest concerns an alleged False Claims Act violation in relation to unapproved pediatric use for Celexa and Lexapro. The company allegedly paid “kickbacks” to encourage physicians to prescribe the drugs.

Click here to view the article, “Forest’s Income Slumps With Set-Aside for Justice Probe”